University of Leeds
Potentiating oncolytic virus therapy for the treatment of Acute Myeloid Leukaemia
Abstract
dc:description.abstractAcute myeloid leukaemia (AML) is a cancer of the blood and bone marrow and is characterised by the overproduction of immature myeloid cells. AML is most common in older adults, 65 being the median age of diagnosis, and is associated with a poor overall survival. Therefore, novel therapies are urgently required. Oncolytic viruses (OV) replicate preferentially within cancerous cells causing cell death and induce innate and adaptive anti-tumour immune responses. However, whilst OV have demonstrated promising results in solid malignancies, their potential for the treatment of AML remains poorly understood. Therefore, herein, we have investigated the efficacy of OVs against AML and developed a combination approach to boost OV efficacy. Using a panel of OV; reovirus, Maraba (MG1), coxsackievirus (CVA21) and herps simplex virus 1716 (HSV-1) we evaluated whether OV-induced pro-inflammatory cytokines or OV-direct oncolysis can kill AML cells, and examined whether apoptotic modulators (SMAC/ BH3 mimetics) could be used to increase OV efficacy.
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of Leeds
- Year dc:date.issued
- 2023
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Askar, Basem Ahmed Ali
- Advisors dc:contributor.advisor
-
- Errington-Mais, Fiona
- Laslo, Peter
- ORCID person:identifier.orcid
Rights
- Language dc:language.dcterms_iso639_2
- eng